A traditional Chinese medicine composition for treating hand-foot syndrome after targeted drug treatment is mainly prepared from the following components by weight: 20-50 parts of Radix Sophorae Flavescentis, 20-50 parts of Herba Taraxaci, 20-50 parts of Flos Chrysanthemi Indici, and 20-50 parts of Herba Cum Radice Violae Yedoensitis, 20-50 parts of Rhizoma Smilacis Glabrae, 30-60 parts of Radix Astragali Seu Hedysari, 10-35 parts of Kochia scoparia (L.) Schrad, 10-45 parts of Carthamus tinctorius L., 15-45 parts of Cortex Radicis Dictamni Dasycarpi, 5-15 parts of Herba Ephedrae, 5-25 parts of Angelica sinensis, 5-25 parts of Rhizoma Ligustici Chuangxiong, 10-30 parts of Radix Rehmanniae, 5-15 parts of Ramulus cinnamomi, 10-30 parts of Cynanchum otophyllum Schneid, 5-15 parts of Semen Sinapis Albae, 5-20 parts of Arisaema heterophyllum Blume, 5-20 parts of Typhonium blumei Nicolson & Sivadasan, and 10-40 parts of Radix Glycyrrhizae.

A traditional Chinese medicine composition for treating hand-foot syndrome after targeted drug treatment is mainly prepared from the following components by weight: 20-50 parts of Radix Sophorae Flavescentis, 20-50 parts of Herba Taraxaci, 20-50 parts of Flos Chrysanthemi Indici, and 20-50 parts of Herba Cum Radice Violae Yedoensitis, 20-50 parts of Rhizoma Smilacis Glabrae, 30-60 parts of Radix Astragali Seu Hedysari, 10-35 parts of Kochia scoparia (L.) Schrad, 10-45 parts of Carthamus tinctorius L., 15-45 parts of Cortex Radicis Dictamni Dasycarpi, 5-15 parts of Herba Ephedrae, 5-25 parts of Angelica sinensis, 5-25 parts of Rhizoma Ligustici Chuangxiong, 10-30 parts of Radix Rehmanniae, 5-15 parts of Ramulus cinnamomi, 10-30 parts of Cynanchum otophyllum Schneid, 5-15 parts of Semen Sinapis Albae, 5-20 parts of Arisaema heterophyllum Blume, 5-20 parts of Typhonium blumei Nicolson & Sivadasan, and 10-40 parts of Radix Glycyrrhizae.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

Provision of a material, which has activity of inhibiting endothelin-converting enzyme and is effective for skin whitening or antihypertension. An endothelin-converting enzyme inhibitor comprising, as an active ingredient, at least one selected from the group consisting of Hiptage candicans, Piper sarmentosum, Solanum stramonifolium, Anaxagorea luzonensis, Smilax corbularia, Ardisia elliptica, Erythrina suberosa, Dactyloctenium aegyptium, Hopea ferrea and extracts thereof.

Provision of a material, which has activity of inhibiting endothelin-converting enzyme and is effective for skin whitening or antihypertension. An endothelin-converting enzyme inhibitor comprising, as an active ingredient, at least one selected from the group consisting of Hiptage candicans, Piper sarmentosum, Solanum stramonifolium, Anaxagorea luzonensis, Smilax corbularia, Ardisia elliptica, Erythrina suberosa, Dactyloctenium aegyptium, Hopea ferrea and extracts thereof.